Straits Times Index
3,139.76 -43.52 (-1.37%) S&P 500
3,951.57 +34.93 (+0.89%) Dow
32,244.58 +382.60 (+1.20%) Nasdaq
11,675.54 +45.02 (+0.39%) Bitcoin USD
27,970.95 -109.37 (-0.39%) CMC Crypto 200
606.85 +7.18 (+1.20%)
GILD Jan 2024 80.000 call
| Previous close | 6.20 |
| Open | 7.35 |
| Bid | 7.60 |
| Ask | 8.05 |
| Strike | 80.00 |
| Expiry date | 2024-01-19 |
| Day's range | 7.35 - 7.61 |
| Contract range | N/A |
| Volume | |
| Open interest | 1.35k |
- Business Wire
Gilead Exercises Option to License Nurix’s IRAK4 Targeted Protein Degrader Development Candidate, NX-0479
FOSTER CITY, Calif. & SAN FRANCISCO, March 20, 2023--Gilead Sciences, Inc. (Nasdaq: GILD) and Nurix Therapeutics, Inc. (Nasdaq: NRIX), a clinical-stage biopharmaceutical company developing targeted protein modulation therapies, today announced that Gilead has exercised its option to exclusively license Nurix’s investigational targeted protein degrader molecule NX‑0479. This bivalent degrader, designated GS-6791, is the first development candidate resulting from the previously announced Nurix-Gil
- Zacks
Gilead Sciences (GILD) Gains But Lags Market: What You Should Know
Gilead Sciences (GILD) closed at $79.85 in the latest trading session, marking a +0.25% move from the prior day.
- Zacks
Gilead (GILD) Gains 34% in 12 Months: Will the Trend Sustain?
Gilead (GILD) gains 34% in the past 12 months as its HIV business and rapidly growing oncology business maintain momentum despite volatility.
